Chang Nancy T. - 24 Feb 2025 Form 4 Insider Report for Galera Therapeutics, Inc. (GRTX)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: GRTX
Reported as of: 24 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Feb 2025, 16:46:22 UTC
Prior SEC filing: 02 Jan 2025
Next SEC filing: 05 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ J. Mel Sorensen, Attorney-in-Fact for Nancy T. Chang

Key filing fact

Chang Nancy T. filed Form 4 for Galera Therapeutics, Inc. (GRTX) on 26 Feb 2025.

Key facts

This page summarizes Chang Nancy T.'s Form 4 filing for Galera Therapeutics, Inc. (GRTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Feb 2025, 16:46.

Change

Previous filing in this sequence was filed on 02 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GRTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +96,000
Change %
Price: $0.000000
Shares after: 96,000
Date: 24 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 96,000
Exercise price: $0.0410
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option shall vest and become exercisable in 36 substantially equal monthly installments measured from December 30, 2024, with the first installment having vested on January 30, 2025, subject to the Reporting Person's continuing service on the Board as a Non-Employee Director through each vesting date.